Cilostazol add-on therapy in patients with mild dementia receiving donepezil: A retrospective study

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ihara, Masafumi ^a   Nishino, Madoka ^b   Taguchi, Akihiko ^c   Yamamoto, Yumi ^a   Hattori, Yorito ^a   Saito, Satoshi ^a   Takahashi, Yukako ^a   Tsuji, Masahiro ^a   Kasahara, Yukiko ^c   Takata, Yu ^b   Okada, Masahiro ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b Sumoto Itsuki Hospital   (Japan)

^c INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; OBSERVATIONAL METHOD; PREDICTION; REFERENCE VALUE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; AGED; DRUG COMBINATION; FOLLOW UP; NEUROPSYCHOLOGICAL TEST; PROGNOSIS;

AGED; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PROGNOSIS; RETROSPECTIVE STUDIES; TETRAZOLES;

EID: 84896280829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089516     Document Type: Article

References (18)

1. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, et al. (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42: 2672-2713.
2. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, et al. (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 136: 2697-2706.
3. Kalaria RN, Akinyemi R, Ihara M (2012) Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 322: 141-147.
4. Kalaria RN, Ihara M (2013) Dementia: Vascular and neurodegenerative pathways-will they meet? Nat Rev Neurol. 487-488.
5. Liu Y, Shakur Y, Yoshitake M, Kambayashi JJ (2001) Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19: 369-386. (Pubitemid 34260705)
6. Kim KY, Shin HK, Choi JM, Hong KW (2002) Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300: 709-715.
7. Fujita Y, Lin JX, Takahashi R, Tomimoto H (2008) Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. Brain Res 1203: 170-176.
8. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, et al. (1989) Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 20: 668-673. (Pubitemid 19139099)
9. Hiramatsu M, Takiguchi O, Nishiyama A, Mori H (2010) Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice. Br J Pharmacol 161: 1899-1912.
10. Park SH, Kim JH, Bae SS, Hong KW, Lee D-S, et al. (2011) Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid b accumulation. Biochem Biophys Res Commun 408: 602-608.
11. Arai H, Takahashi T (2009) A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am J Geriatr Psychiatry 17: 353-354.
12. Sakurai H, Hanyu H, Sato T, Kume K, Hirao K, et al. (2013) Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 13: 90-97.
13. Taguchi A, Takata Y, Ihara M, Kasahara Y, Tsuji M, et al. (2013) Cilostazol improves cognitive function in patients with mild cognitive impairment: A retrospective analysis. Psychogeriatrics 13: 164-169.
14. Kamiyama K, Wada A, Sugihara M, Kurioka S, Hayashi K, et al. (2010) Potential hippocampal region atrophy in diabetes mellitus type 2: a voxel-based morphometry VSRAD study. Jpn J Radiol 28: 266-272.
15. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, et al. (2010) Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968.
16. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12: 723-738.
17. Chow N, Bell RD, Deane R, Streb JW, Chen J, et al. (2007) Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A 104: 823-828. (Pubitemid 46154695)
18. Weller RO, Djuanda E, Yow HY, Carare RO (2009) Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117: 1-14.